Twist Bioscience Corporation (TWST) Misses Q1 EPS by 86c, Revenues Beat; Offers FY20 Revenue Mid-Point Guidance Below Consensus

Go back to Twist Bioscience Corporation (TWST) Misses Q1 EPS by 86c, Revenues Beat; Offers FY20 Revenue Mid-Point Guidance Below Consensus

Twist Bioscience Corporation (TWST) Confirms Settlement with Agilent (A)

February 6, 2020 4:09 PM EST

Twist Bioscience Corporation (NASDAQ: TWST) announced it has reached a settlement agreement with Agilent Technologies (NYSE: A) to resolve all claims and counterclaims in the trade secret litigation filed by Agilent on February 3, 2016.

Under the terms of the... More

UPDATE: Cowen says Twist Bioscience Corporation (TWST), Agilent Technologies (A) may be close to a legal settlement

February 6, 2020 1:44 PM EST

(Updated - February 6, 2020 1:45 PM EST)

Cowen analyst Doug Schenkel says Twist Bioscience Corporation (NASDAQ: TWST), Agilent Technologies (NYSE: A) may be close to a legal settlement.

From the analyst, "Developments this afternoon in the Agilent-Twist... More